newsfilter
← Latest News
PR Newswire·

Bulletin from the Annual General Meeting in BioArctic AB (publ)

BIOA
  • BioArctic AB held its Annual General Meeting in Stockholm on May 28, 2026, to adopt resolutions on financial statements, board composition, & shareholder incentives.
  • The meeting approved the income statement & balance sheet for 2025, resolved to pay a dividend of SEK 2 per share, & set June 1, 2026, as the record date.
  • The board of directors & CEO were discharged from liability for the financial year 2025.
  • Ordinary board members Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist, & Mikael Smedeby were re-elected, while Philip Scheltens & Linda Nilsson were elected as new members; Eugen Steiner was re-elected as chairperson.
  • Remuneration for board members was set at SEK 875,000 for the chairperson, SEK 315,000 for other ordinary members, & specified amounts for committee chairs & members.
  • Öhrlings PricewaterhouseCoopers AB (PwC) was elected as auditor until the next Annual General Meeting, with Niclas Bergenmo appointed as the auditor in charge.
  • The board was authorized to issue new shares, warrants, & convertibles up to a 10 percent increase in share capital without shareholder pre-emption rights.
  • A three-year incentive program was approved for employees, offering up to 235,000 performance-based share units (PSUs) vesting on May 28, 2029, subject to total shareholder return (TSR), operational, & sustainability targets.
  • The TSR condition requires an accumulated return of at least 30 percent for B-shares on Nasdaq Stockholm during the measurement period.
  • Hedging arrangements were approved, allowing the board to acquire up to 730,000 shares, issue up to 309,000 warrants, & transfer up to 235,000 B-shares to participants.
  • Updated guidelines for senior executive remuneration were adopted, setting maximum variable remuneration at 150 percent of fixed salary for the CEO & 80 percent for other senior executives.
  • The company, which developed Leqembi® in partnership with Eisai, focuses on neurodegenerative diseases using its BrainTransporter™ technology.